1 6
aspects of ageing may be human-specific. Only a few studies have focused on data from 1 0 0 humans. For instance, Aliper et al. (2016) [16] applied the GeroScope algorithm [17] to 1 0 1 identify drugs mimicking the signalome of young human subjects based on differential 1 0 2 expression of genes in signalling pathways involved in the ageing process. Another with age in the human brain with drug-mediated gene expression changes in cell lines 1 0 5
from the Connectivity Map [19] .
of ageing-related terms ( Fig 1C -left) . Equivalently, drugs were then associated with 1 7 1 these terms through association with their targets using the list of genes defining each 1 7 2 term according to the DAVID knowledgebase [37] and the biological database network 1 7 3
[38]. This mapping procedure resulted in a set of terms from each data source related to 1 7 4 each drug (drug-related terms) ( Fig 1C -right) . Analogously to the gene-based association analysis, we calculated for each level if the 1 7 9
overlap between ageing-related terms and drug-related terms was statistically significant 1 8 0 using a Fisher's exact test. This procedure generated 6 lists of ranked compounds in 1 8 1 addition to the gene-based analysis (S1 tables). Notably, when we evaluated the 1 8 2 correlation between the ranking of compounds in the different lists (Fig 2A) Because in any enrichment analysis there is a potential for research bias, we performed 1 9 0 random permutations to simulate the enrichment of each drug for a different set of terms 1 9 1 on each level. None of the top-ranked drugs on each list ranked higher than in the 1 9 2 analysis in more than 1.7% of the simulations (Table A in S2 text). We also quantified fraction of drugs considered in each analysis ( Fig 2B) . The enrichment for pro-longevity 1 9 6 compounds was quantified by calculating the area under the curve (AUC) generated by 1 9 7
plotting these two variables. The maximum AUC was obtained when biological 1 9 8 processes or molecular functions (AUC = 0.69) was used as the comparator ( S2 text). The use of genes showed the lowest enrichment when non-statistically 2 0 0 significant drugs are considered (AUC = 0.59), which suggests that the use of higher 2 0 1 biological levels to calculate the inference improves the prediction capabilities, and that 2 0 2 the use of genes leads to a loss power to rank drugs targeting a low proportion of with an AUC equal or higher than the analysis. All lists showed a higher enrichment 2 0 8 than expected by chance (AUC > 0.5 and p-value < 0.05, Table B in S2 text). When we 2 0 9
only considered the first 20 top-ranked drugs, we observed that using biological 2 1 0 processes or cellular components to perform the comparison showed the highest 2 1 1 proportion of pro-longevity drugs (45%), while only 2 pro-longevity drugs (10%) were 2 1 2 found among the top 20 drugs when KEGG pathways are used. Considering the lack of overlap between the ranked lists using the different data 2 1 5 sources, we decided to integrate the results into a single list accounting for the best average ranking ( Table 2 , S1 tables), we found 3 drugs that have extended lifespan and 7 are approved for human use. The HSP-90 inhibitor tanespimycin as a novel pro-longevity drug 2 2 5
Leading the joint ranking was tanespimycin, also known as 17-AAG, a well-
characterized HSP-90 inhibitor that has been shown to activate the transcription factor 2 2 7
HSF-1 and induce a heat shock response in multiple model organisms [26] . As a proof-
of-principle, we decided to investigate whether tanespimycin could activate HSF-1 and 2 2 9
extend lifespan in the nematode worm C. elegans. To test the efficacy of tanespimycin 2 3 0 dosing in C. elegans, we grew worms expressing mCherry under the control of an HSF- tanespimycin. Worms were exposed to tanespimycin continuously from the first larval HSF-1 transcriptional reporter, starting at 25 µM and peaking at 100 µM ( Fig 3A-B) . Similarly, exposure to tanespimycin plates exclusively in adulthood resulted in and reproduction, we exposed worms to 100 µM tanespimycin plates from the first day 2 4 7 of adulthood. Tanespimycin treatment significantly extended median and maximal 2 4 8 lifespan compared to vehicle-treated controls ( Fig 3C) . To determine whether the 2 4 9 effects of tanespimycin on lifespan require hsp-90, we also exposed worms to an hsp-90 dependent manner, but that severe depletion of HSP-90 is toxic to animals, 2 5 5 despite the activation of protective stress responses.
ageing drugs. Using annotated databases, our method evaluated the enrichment for pro-
longevity of all compounds analysed, rather than only those with significant scores, and 3 0 1
we observe that in all cases pro-longevity compounds are ranked higher than expected 3 0 2 by chance. Although tanespimycin acts as a senolytic [31] , and has been predicted to be A limitation of this study is that it is based on previous knowledge about drug-protein 3 0 7
interactions, which for non-commonly studied drugs is incomplete. This may explain 3 0 8
why we observed many anti-cancer and well-known drugs in our results. While we 3 0 9
assessed this bias using permutations and we found no significant effect on our results, 3 1 0 further research is needed to increase the drug-protein interactome data using, for 3 1 1 example, high-throughput technologies like those currently available for kinases [49] .
3 1 2
While we combined the results from the different data sources using a strategy based on 3 1 3 ranks, we hypothesise that the integration of these results using other methods may lead 3 1 4
to a list with a higher enrichment for pro-longevity drugs. Additionally, further 3 1 5
experimental testing is required on the lists produced in this study, particularly those 3 1 6 generated by using gene ontology terms, which presented the higher enrichment for pro-3 1 7 longevity drugs. An inherent limitation of inferred associations is that they do not it is unknown if the drugs will deaccelerate ageing or the opposite. While we indirectly 3 2 0 assessed this using an interaction-based similarity analysis between the drugs, resulting is that we validated the results of this study using experiments in animal models probability of observing an interaction by chance. The overall confidence score ranges 3 4 6 from 0 to 1, where a value of 0.4 or greater is considered as medium confidence, and a 3 4 7 score equal to or higher than 0.7 is regarded as high confidence. To obtain a reliable set 3 4 8
of interactions, we removed all interactions with a confidence score lower than 0.7. The proteins, only the cases where the chemical activates or inhibits a protein were retained.
3 5 3
To focus on drugs in development or approved for human use, we filtered the chemicals dataset will be referred as "drugs" or "compounds" throughout this article. Drug-related terms: We mapped the targets of each drug in the drug-protein 3 6 5
interaction dataset to multiple biological levels by using the information about the genes 3 6 6 that define each level analysed. We downloaded the gene-centric definitions of GO related genes with a confidence equal of higher than 0.9 were considered. of selecting a set of ageing-related genes from a particular study or database, we used The aging effect of chemotherapy on cultured human mesenchymal stem cells. 
